Switching HIV Treatment from Protease Inhibitors to Nevirapine in Children
Author Information
Author(s): Gonzalez-Tome M Isabel, Amador Jose Tomas Ramos, Peña M Jose Mellado, Gomez M Luisa Navarro, Conejo Pablo Rojo, Fontelos Pablo Martin
Primary Institution: Division of Immunodefiencies, Hospital 12 de Octubre, Madrid, Spain
Hypothesis
Can substituting protease inhibitors with nevirapine improve metabolic abnormalities in HIV-infected children?
Conclusion
Switching from protease inhibitors to nevirapine improved the lipid profile in HIV-infected children, but did not significantly change body fat or lipodystrophy.
Supporting Evidence
- All patients had stable HIV-1 RNA levels below 50 copies/ml before switching.
- Median decrease in cholesterol was observed, although not statistically significant.
- HDL-cholesterol levels increased significantly during the study.
- Most patients maintained viral load below 50 copies/ml after the switch.
Takeaway
The study looked at seven kids with HIV who switched their medicine to a simpler one, and it helped their cholesterol levels get better.
Methodology
Seven children were switched from a stable protease inhibitor regimen to nevirapine, and their clinical, laboratory, and anthropometric data were assessed every 3 months.
Potential Biases
The small sample size and lack of a control group may introduce bias in the results.
Limitations
The study included only seven patients and followed them for only 12 months, which may not be sufficient to detect significant changes.
Participant Demographics
The participants included 5 boys and 2 girls, with a median age of 120 months, all Caucasian, and mostly infected through vertical transmission.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website